# Gemini-3-Flash Review

**Role:** External referee review
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-02-19T11:00:10.644363
**Route:** Direct Google API + PDF
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 17555 in / 1407 out
**Response SHA256:** a99ba8716287c4a6

---

This review evaluates "Click to Prescribe: Do Electronic Prescribing Mandates Reduce Opioid Mortality?" for potential publication.

---

## 1. FORMAT CHECK
- **Length**: The paper is 31 pages, which meets the standard for a substantive submission to a top-tier journal.
- **References**: Broadly sufficient, covering both the specific opioid policy literature (Buchmueller & Carey, 2018; Alpert et al., 2022) and the necessary modern econometrics (Callaway & Sant’Anna, 2021; Sun & Abraham, 2021).
- **Prose**: Major sections are written in appropriate academic paragraph form.
- **Section depth**: Each section (Intro, Data, Methodology, Results) is substantive and well-developed.
- **Figures**: Figures 1–4 are high quality, clearly labeled, and present visible data trends. 
- **Tables**: Tables 1–4 provide comprehensive real-number data; no placeholders are used.

---

## 2. STATISTICAL METHODOLOGY
- **Standard Errors**: Consistently reported in parentheses for all coefficients (e.g., Table 2, Table 3).
- **Significance Testing**: P-values and/or stars are provided for all major estimates.
- **Confidence Intervals**: 95% CIs are included for the main results in Tables 2 and 3.
- **Sample Sizes**: N (observations and states) is reported for all regressions.
- **Staggered Adoption**: The paper correctly avoids simple TWFE as its primary estimator, instead utilizing **Callaway & Sant’Anna (2021)** and **Sun & Abraham (2021)** to address potential bias from heterogeneous treatment effects and staggered timing. This is a significant methodological strength.
- **Log Specification**: The author correctly notes that the log specification (Panel D, Table 2) handles the skewed distribution of mortality data better than level estimates, which explains the jump in precision.

---

## 3. IDENTIFICATION STRATEGY
The identification strategy is highly credible.
- **Parallel Trends**: Visual evidence from the event study (Figure 4) and Sun-Abraham results (Section C.2) suggests no pre-existing trends.
- **Built-in Placebo**: The use of Synthetic Opioid deaths (T40.4) as a placebo is a clever and powerful identification check. Because EPCS mandates only affect the "legitimate" prescribing channel, the null result on illicit fentanyl deaths strongly suggests the Rx opioid result is not driven by unobserved shocks to the general drug environment.
- **Exogeneity**: The author makes a compelling case that the timing was driven by federal pressure (SUPPORT Act) and infrastructure lags rather than local mortality spikes.
- **Limitations**: The author honestly discusses CDC data suppression and the overlap of the COVID-19 pandemic with the treatment wave.

---

## 4. LITERATURE
The literature review is well-positioned. It distinguishes between *information* interventions (PDMPs) and *infrastructure* interventions (EPCS).

**Suggested Addition**:
While the paper cites the foundational "staggered DiD" papers, it would benefit from citing work on **"Event Studies with Missing Data"** or **"Sample Selection in DiD"** given the CDC suppression issue (approx. 25% of observations missing).
- *Relevant Paper*: **Brot-Goldberg et al. (2023)** or similar work on censoring in mortality data.

```bibtex
@article{Horwitz2021,
  author = {Horwitz, Jill and Davis, Corey S. and McClelland, Lois S. and Fordon, Rebecca S. and Meara, Ellen},
  title = {The Problem of Data Quality in Analyses of Opioid Regulation: The Case of Prescription Drug Monitoring Programs},
  journal = {NBER Working Paper},
  year = {2021},
  volume = {24947}
}
```
*(Note: Author cites this in the text but ensuring it is used to justify the handling of the "suppressed" cells in Section 4.2 would be beneficial.)*

---

## 5. WRITING QUALITY
- **Narrative Flow**: Excellent. The paper moves logically from the vulnerability of paper pads to the econometric results.
- **Accessibility**: The distinction between T40.2 (Rx) and T40.4 (Fentanyl) is explained clearly, making the drug-class placebo test intuitive even for a general interest reader.
- **Magnitudes**: The author does a good job of moving beyond "p < 0.05" to explain that the 18% reduction, while significant, targets a shrinking portion of the overall crisis.

---

## 6. CONSTRUCTIVE SUGGESTIONS
1.  **Selection on Suppression**: In Section 7.3, the author notes the CDC suppresses counts < 10. If EPCS mandates *cause* a state to drop below 10 deaths, they might drop out of the sample, potentially biasing results toward zero (as the "most successful" cases are censored). I suggest a robustness check using a **Tobit-style DiD** or a **Poisson Pseudo-Maximum Likelihood (PPML)** estimator, which handles zeros/small counts and non-linearities more gracefully than OLS or log-linear models.
2.  **State-Specific Trends**: While the event study is clean, a robustness check adding state-linear trends (though controversial in some DiD circles) or "region-by-year" fixed effects would satisfy more skeptical referees.
3.  **Substitution Analysis**: The author mentions substitution (Alpert et al., 2022). Although the placebo test shows no *increase* in fentanyl deaths, a more explicit test for "total opioid deaths" (T40.0-T40.6) would confirm whether the 18% Rx reduction is a net saving of lives or merely a shift in drug type.

---

## 7. OVERALL ASSESSMENT
This is a very strong, technically proficient paper. It tackles a relevant policy question using state-of-the-art causal inference methods. The "null-in-levels, significant-in-logs" result is handled with maturity, and the built-in placebo test provides high confidence in the identification. The primary weakness is the moderate sample size and the data suppression issue, but these are inherent to the data source and are handled as well as possible.

---

## DECISION

**DECISION: MINOR REVISION**